Literature DB >> 26032929

Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan.

Katsutoshi Sugimoto1, Fuminori Moriyasu, Yoshiyuki Kobayashi, Kazuhiro Saito, Hirohito Takeuchi, Saori Ogawa, Mayumi Ando, Takatomo Sano, Toshifumi Mori, Yoshihiro Furuichi, Ikuo Nakamura.   

Abstract

PURPOSE: This clinical study was conducted to evaluate the safety and short-term outcomes of irreversible electroporation (IRE) for the treatment of patients with hepatocellular carcinoma (HCC) in Japan.
MATERIALS AND METHODS: The study was designed in a prospective setting. Five patients (3 men and 2 women; mean age, 66.6 ± 5.8 years) with 6 HCCs were enrolled and treated using percutaneous ultrasound (US)-guided IRE. Safety was assessed based on adverse events and laboratory values. Local control was assessed using contrast-enhanced US with a perflubutane microbubble contrast agent, contrast-enhanced multiphase CT, and gadoxetic acid-enhanced MRI (EOB-MRI) at designated points.
RESULTS: The tumors ranged in diameter from 11 to 28 mm (mean diameter, 17.5 ± 6.3 mm). Five of the 6 tumors (83 %) were successfully treated, with no local recurrence to date (mean follow-up 244 ± 55 days). In 1 lesion located in liver segment 1, residual tumor was diagnosed at 7 days after intervention by follow-up EOB-MRI. No serious complications related to the IRE procedure were observed.
CONCLUSION: The results of this study suggest that image-guided percutaneous IRE can achieve satisfactory local disease control, particularly for small HCCs, and is well tolerated by patients.

Entities:  

Mesh:

Year:  2015        PMID: 26032929     DOI: 10.1007/s11604-015-0442-1

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  20 in total

Review 1.  Microbubble-enhanced US in body imaging: what role?

Authors:  Stephanie R Wilson; Peter N Burns
Journal:  Radiology       Date:  2010-10       Impact factor: 11.105

2.  Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation.

Authors:  Edward W Lee; Christopher T Loh; Stephen T Kee
Journal:  Technol Cancer Res Treat       Date:  2007-08

3.  Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial.

Authors:  Fuminori Moriyasu; Kouichi Itoh
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

4.  Ablation of perivascular hepatic malignant tumors with irreversible electroporation.

Authors:  T Peter Kingham; Ami M Karkar; Michael I D'Angelica; Peter J Allen; Ronald P Dematteo; George I Getrajdman; Constantinos T Sofocleous; Stephen B Solomon; William R Jarnagin; Yuman Fong
Journal:  J Am Coll Surg       Date:  2012-06-16       Impact factor: 6.113

5.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

6.  Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas.

Authors:  Hyunchul Rhim; Mi Hee Lee; Young-Sun Kim; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2008-05       Impact factor: 3.959

7.  Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.

Authors:  Robert C G Martin; Kelli McFarland; Susan Ellis; Vic Velanovich
Journal:  Ann Surg Oncol       Date:  2012-11-06       Impact factor: 5.344

8.  Irreversible electroporation: an in vivo study with dorsal skin fold chamber.

Authors:  Zhenpeng Qin; Jing Jiang; Gary Long; Bruce Lindgren; John C Bischof
Journal:  Ann Biomed Eng       Date:  2012-11-22       Impact factor: 3.934

9.  Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation.

Authors:  Robert C G Martin; Prejesh Philips; Susan Ellis; David Hayes; Sandeep Bagla
Journal:  BMC Cancer       Date:  2014-07-26       Impact factor: 4.430

10.  A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Authors:  Massimo Valerio; Louise Dickinson; Afia Ali; Navin Ramachandran; Ian Donaldson; Alex Freeman; Hashim U Ahmed; Mark Emberton
Journal:  Contemp Clin Trials       Date:  2014-07-26       Impact factor: 2.226

View more
  16 in total

1.  Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy.

Authors:  A Giorgio; F Amendola; A Calvanese; E Ingenito; B Santoro; P Gatti; E Ciracì; P Matteucci; V Giorgio
Journal:  J Ultrasound       Date:  2019-03-06

2.  The interaction between irreversible electroporation therapy (IRE) and embolization material using a validated vegetal model: an experimental study.

Authors:  Philip Chan; Catriona McLean; Stephen Chan; Gerard S Goh
Journal:  Diagn Interv Radiol       Date:  2019-07       Impact factor: 2.630

3.  Irreversible electroporation of malignant liver tumors: Effect on laboratory values.

Authors:  Mohammed Alnaggar; Ammar M Qaid; Jibing Chen; Lizhi Niu; Kecheng Xu
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

4.  Multimodality imaging to assess immediate response following irreversible electroporation in patients with malignant hepatic tumors.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Kazuhiro Saito; Yoshiyuki Kobayashi; Takao Itoi
Journal:  J Med Ultrason (2001)       Date:  2016-12-08       Impact factor: 1.314

5.  Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.

Authors:  Vincenza Granata; Elisabetta de Lutio di Castelguidone; Roberta Fusco; Orlando Catalano; Mauro Piccirillo; Raffaele Palaia; Francesco Izzo; Adolfo D'Errico Gallipoli; Antonella Petrillo
Journal:  Radiol Med       Date:  2015-09-07       Impact factor: 3.469

Review 6.  Irreversible electroporation in primary and metastatic hepatic malignancies: A review.

Authors:  Tianchu Lyu; Xifu Wang; Zhanliang Su; Junjie Shangguan; Chong Sun; Matteo Figini; Jian Wang; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

Review 7.  Ablation of hepatic malignant tumors with irreversible electroporation: A systematic review and meta-analysis of outcomes.

Authors:  Guo Tian; Qiyu Zhao; Fen Chen; Tian'an Jiang; Weilin Wang
Journal:  Oncotarget       Date:  2017-01-24

Review 8.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

9.  Electric Ablation with Irreversible Electroporation (IRE) in Vital Hepatic Structures and Follow-up Investigation.

Authors:  Xinhua Chen; Zhigang Ren; Tongyin Zhu; Xiongxin Zhang; Zhiyi Peng; Haiyang Xie; Lin Zhou; Shengyong Yin; Junhui Sun; Shusen Zheng
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

Review 10.  Irreversible electroporation: state of the art.

Authors:  Peter Gk Wagstaff; Mara Buijs; Willemien van den Bos; Daniel M de Bruin; Patricia J Zondervan; Jean Jmch de la Rosette; M Pilar Laguna Pes
Journal:  Onco Targets Ther       Date:  2016-04-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.